Case 1: Patient P. 56 years old complains about heartburn, more at might and in the morning: burning sensation behind the sternum, appearing immediately after throat hurn with a sour taste. EGDS revealed inflammatory eating; nausea, sore throat, burp wi a sive form of changes in the distal esophagus characteristic of the non-erosive torm l eastroesophageal reflux disease. astroe Station 1 tation 1. Identify the problem (diagnosis): Identity 2. Choose your P-medication for this condition: 3 Dosage form Dosage form Dosage Station 2 5. Pharmacokinetics of the drug 6. Mechanism of action 7. Write a prescription Station 3 8. Duration of treatment 9. Side effects 10. Contraindications

Reading File

Finding Sources

Reading File

I now have sufficient information from the textbooks. Let me compile a comprehensive answer for all stations.

Case 1: GERD — Non-Erosive Form (NERD)

Station 1

1. Diagnosis

Non-Erosive Reflux Disease (NERD) — a subtype of Gastroesophageal Reflux Disease (GERD) in which patients have typical reflux symptoms (heartburn, regurgitation, sour taste, burning behind the sternum) with inflammatory mucosal changes on EGDS but without visible erosions or ulceration of the esophageal mucosa.

2. P-Medication (Drug of Choice)

Omeprazole (a Proton Pump Inhibitor — PPI)

PPIs are the first-line therapy for GERD/NERD. Omeprazole is the prototype drug of this class and is widely recommended for both erosive and non-erosive GERD.

3. Dosage Form

Enteric-coated delayed-release capsules (or tablets) — oral form.

Enteric coating is essential because PPIs are acid-labile and must reach the small intestine before absorption.

4. Dose

20 mg once daily, taken 30–60 minutes before the first meal of the day (breakfast).

For persistent symptoms: 20–40 mg once daily.

Station 2

5. Pharmacokinetics

(Yamada's Textbook of Gastroenterology, 7th ed.; Katzung's Basic and Clinical Pharmacology, 16th ed.)

Parameter	Detail
Absorption	Absorbed in the small intestine after enteric-coated tablet dissolves; bioavailability ~35–65% (increases with repeat dosing)
Protein binding	~95%
Distribution	Prodrug; concentrates selectively in the acidic parietal cell canaliculi
Metabolism	Hepatic — primarily by CYP2C19 (major) and CYP3A4 (minor) → active sulfenamide form in the parietal cell
Elimination	Renal (~77%) and biliary/fecal; plasma half-life ~0.5–1.5 hours, but duration of acid suppression is 24+ hours (irreversible enzyme binding)
Onset	~1–2 hours; maximal effect after several days of dosing

— Yamada's Textbook of Gastroenterology, Proton Pump Inhibitors section

6. Mechanism of Action

Omeprazole is a prodrug. In the acidic secretory canaliculi of the gastric parietal cell, it is converted to its active sulfenamide form, which irreversibly inhibits H⁺/K⁺-ATPase (the proton pump) — the final common pathway of gastric acid secretion.

Because binding is covalent and irreversible, acid suppression persists until new pump proteins are synthesized (~18–24 hours).
It blocks both basal and stimulated acid secretion (regardless of the stimulus — histamine, gastrin, or acetylcholine).
This reduces the volume of acid refluxed into the esophagus, relieving heartburn and promoting mucosal healing.

— Katzung's Basic and Clinical Pharmacology, 16th ed.

7. Prescription

Rp.
  Omeprazoli 0.02 (20 mg)
  D.t.d. No. 28 in caps. enterosolv.
  S. 1 capsule once daily, 30–60 min before breakfast.

Station 3

8. Duration of Treatment

NERD (non-erosive GERD): Initial course 4–8 weeks.
If symptom relief is achieved: step-down to on-demand therapy or lowest effective dose.
Long-term/maintenance therapy may be considered for patients with frequent relapse.

9. Side Effects

Frequency	Side Effect
Common	Headache, nausea, diarrhea, abdominal pain, flatulence
Less common	Constipation, dry mouth, dizziness
Long-term use	Hypomagnesaemia, hypocalcaemia, increased risk of Clostridioides difficile infection, vitamin B₁₂ deficiency, increased fracture risk (osteoporosis)
Rare	Interstitial nephritis, hepatitis, gynecomastia
Drug interactions	Reduces absorption of drugs requiring acidic environment (ketoconazole, iron, atazanavir); may increase clopidogrel metabolism interference via CYP2C19

10. Contraindications

Hypersensitivity to omeprazole, other PPIs, or any component of the formulation (including substituted benzimidazoles)
Concurrent use with rilpivirine or nelfinavir (antiretrovirals whose absorption is pH-dependent)
Caution in severe hepatic impairment (dose reduction required)
Not for use as empirical therapy when gastric malignancy has not been excluded (PPIs may mask symptoms of cancer)
Pregnancy: use only if clearly indicated (Category C)

— Katzung's Basic and Clinical Pharmacology, 16th ed.; Yamada's Textbook of Gastroenterology, 7th ed.

Why not fomentadine

You likely mean famotidine (an H₂-receptor antagonist). Here's why a PPI like omeprazole is preferred over famotidine for this case:

PPIs vs. H₂-Blockers (Famotidine) in GERD/NERD

Mechanism Comparison

Drug	Target	Acid suppression
Omeprazole (PPI)	Irreversibly blocks H⁺/K⁺-ATPase (the final common pathway)	~90% reduction in 24-hour acid output
Famotidine (H₂-blocker)	Blocks histamine H₂ receptors on parietal cells only	~70% reduction, primarily nocturnal

Why Famotidine is Inferior Here

Tachyphylaxis (tolerance) — H₂-blockers lose efficacy within 2–6 weeks of regular use due to upregulation of H₂ receptors and compensatory gastrin rise. PPIs do not have this problem.
Incomplete suppression — Famotidine only blocks the histamine pathway. Gastrin and acetylcholine can still stimulate the proton pump directly, so acid secretion is never fully suppressed.
PPIs heal mucosa faster — In all GERD trials, PPIs produce significantly higher rates of symptom relief and mucosal healing compared to H₂-blockers.
Guidelines preference — All major guidelines (ACG, AGA, NICE) recommend PPIs as first-line for GERD/NERD. H₂-blockers are reserved for:
- Mild/infrequent heartburn (on-demand use)
- Patients who cannot tolerate PPIs
- Nocturnal acid breakthrough as an add-on to PPIs

When Famotidine IS Appropriate

Mild, intermittent heartburn not meeting GERD criteria
On-demand relief (e.g., after a large meal)
As add-on at bedtime for nocturnal symptoms despite PPI use
Patients with PPI hypersensitivity or drug interactions

In summary: This patient has confirmed GERD (by EGDS) with daily, troublesome symptoms — that profile requires the stronger, sustained acid suppression that only a PPI provides. Famotidine would likely fail within weeks due to tolerance.

This is a shared conversation. Sign in to Orris to start your own chat.